



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/62, 15/16, 15/36, C07K 14/575, 14/02</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/57289</b> <b>(43) International Publication Date:</b> 11 November 1999 (11.11.99)
<b>(21) International Application Number:</b> PCT/US99/08238 <b>(22) International Filing Date:</b> 14 April 1999 (14.04.99) <b>(30) Priority Data:</b> 09/072,323      4 May 1998 (04.05.98)      US <b>(71) Applicant:</b> MICHIGAN STATE UNIVERSITY [US/US]; 238 Administration Building, East Lansing, MI 48824-1046 (US). <b>(71)(72) Applicants and Inventors:</b> PUMPENS, Paul [LV/LV]; Baznicas 27/29-21, LV-1010 Riga (LV). BORISOVA, Galina [LV/LV]; Merkela 2-6, LV-1050 Riga (LV). SKRASTINA, Dace [LV/LV]; Dammes 34-10, LV-1069 Riga (LV). MEZULE, Guna [LV/LV]; Skujenes 10-1, LV-1055 Riga (LV). <b>(72) Inventor:</b> IRELAND, James, J.; 2805 Brentwood Avenue, East Lansing, MI 48823 (US). <b>(74) Agent:</b> DAIGNAULT, Ronald, A.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> INHIBIN-HBc FUSION PROTEIN <b>(57) Abstract</b> <p>A fusion protein formed of an antigenic inhibin peptide inserted into hepatitis B capsid protein is expressed from a chimeric gene forming an effective immunogen which induces anti-inhibin antibodies when administered to a host animal.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Inhibin-HBc Fusion Protein

### Field of the Invention:

This invention relates to useful immunogenic molecules formed of an antigenic inhibin peptide and hepatitis B capsid protein. More particularly, an antigenic inhibin peptide is genetically inserted into the hepatitis B capsid protein, resulting in the production of a fusion protein which induces the production of anti-inhibin antibodies when administered to host animals, even in the absence of adjuvant.

### Background of the Invention:

The inhibin protein family includes dimeric glycoproteins produced by the gonads which act in an endocrine fashion to suppress secretion of follicle stimulating hormone (FSH) from the pituitary gland. Since FSH is the major hormone involved in stimulation of ovulation and sperm production, inhibin-induced suppression of FSH diminishes the rates of ovulation and sperm production. Inhibins are therefore natural suppressers of the reproductive process.

Active immunization of farm animals against inhibin increases the rates of ovulation and sperm production, demonstrating that inhibin-based immunogens are important agents to enhance fertility in farm animals, including swine, bovine, ovine, and equine animals. See, for example: Brown, et al., *J.Reprod.Fertility* 90:199-205, 1990; King, et al., *J.Animal Science* 71:975-982, 1993; Morris, et al., *J.Reprod.Fertility* 97:255-261, 1993; McCue, et al., *Theriogenology* 38:823-831, 1992; Voglmayer, et al., *Biol.Reprod.* 42:81-86, 1990; Martin, et al., *Biol.Reprod.* 45:73-77, 1991.

The immunization of gilts with a small peptide fragment of the bovine inhibin  $\alpha_c^{1-26}$  subunit chemically conjugated to human alpha globulin (HAG) and mixed with Freund's adjuvant resulted in a minor increase in FSH during the follicular phase and a decrease in FSH during the luteal phase, without effect on serum concentrations of estradiol, progesterone, or luteinizing hormone (King, et al., *J. Animal Science* 71:975-982, 1993). Despite the relatively minor increase in FSH during the follicular phase and decrease during the early luteal phase, immunized

gilts had a 39% greater ovulation rate as compared with controls. In addition, lifetime proliferacy of the immunized gilts was enhanced.

While the above described merits of using the antigenic inhibin peptide to neutralize inhibins and enhance fertility are known, a commercially useful vaccine is not available.

The development of vaccines based on small antigenic epitopes is hampered by the inability of the small antigen to elicit a good immune response in a host animal. The use of carrier immunogens provides some assistance in the immune response, but often decreases the specific activity and yield of the response against the desired antigen. Methods for conjugation of antigens to carrier agents are costly, and generally utilize hazardous chemicals. Covalent coupling of antigen to a carrier protein is inherently variable, resulting in an antigen with an imprecise structure, compromising vaccine potency. The use of adjuvants also tends to decrease the yield of specific antibodies and can be harmful to the animal host, causing abscesses, skin lesions, and hypersensitivity. These factors are unacceptable for the production of a commercially useful vaccine.

These disadvantages are overcome in the present invention by using recombinantly produced fusion proteins as immunogens, whose structure is well defined. Synthesis of the inventive immunogens does not require hazardous chemical treatments, and the molecules are herein demonstrated to induce a desired anti-inhibin immune response, even in the absence of additional adjuvants.

### Summary of the Invention

It has now been found that an inhibin:hepatitis B capsid protein fusion (Inh:HBc) provides a useful, defined, easily produced, immunogenic molecule which, upon administration to host animals, induces a fertility-enhancing, anti-inhibin immune response, even in the absence of additional adjuvant. The Inh:HBc fusion protein is produced by inserting a first nucleic acid sequence encoding an antigenic inhibin peptide into a second nucleic acid sequence encoding hepatitis B capsid protein and expressing a fusion protein in a cellular host. When administered to host animals, particularly to farm animals, the Inh:HBc fusion protein induces an anti-inhibin immune response. The anti-inhibin response results

in enhanced fertility, measured, for example, as an increase in ovulation rates in immunized animals, and preferably, as an increase in lifetime proliferation.

In a preferred embodiment of the invention, a preferred antigenic inhibin peptide is an amino acid sequence of the inhibin  $\alpha_c$  subunit. For example, a preferred antigenic peptide of the invention is formed of the first 25 N-terminal amino acids of the inhibin alpha-C subunit (bINH $\alpha_c$ <sup>1-25</sup>).

It was unexpectedly discovered that inhibin antigenic peptide inserted at position 78 of the HBc protein results in a preferred fusion protein inducing useful antibody titer in host animals with good anti-inhibin specificity. In this construct, the inhibin antigenic peptide is inserted in place of a major immunological region of HBc Ag.

#### Brief Description of the Figures

Figure 1A is a photograph of a silver stained gel showing production of Inh:HBc-78.

Figure 1B is a photograph of an immunoblot of Inh:HBc-78 probed with anti-inhibin antibody.

Figure 1C is a photograph of a silver stained gel showing production of Inh:HBc-144.

Figure 1D is a photograph of an immunoblot of Inh:HBc-144 probed with anti-inhibin antibody.

Figure 2 is a electron micrograph showing capsid formation of Inh:HBc-78.

Figure 3 is a graph showing anti-inhibin antibody titers in mice immunized with Inh:HBc-78 with Freund's; Inh:HBc, Inh:HBc-78 without Freund's; Inh:HBc-144 with Freund's; and Inh:HBc-144 without Freund's.

Figure 4 is a graph showing anti-native inhibin antibody titers in mice immunized with Inh:HBc-78 and Inh:HBc-144 with and without Freund's.

Figure 5 is a graph showing anti-inhibin titers in gilts immunized with Inh:HBc-144 and Inh:HBc-78.

### Detailed Description of the Invention

In the preferred embodiments of the invention, an immunogenic carrier molecule, the hepatitis B capsid protein (HBc), is modified to include an inserted antigenic inhibin peptide. The inserted inhibin peptide is positioned such that it does not preclude correct assembly of the HBc protein into core particles and is recognized as antigenic in host systems. As shown below, the inhibin antigenic peptide is preferentially inserted at position 78 of the HBc protein.

When used as a vaccine, the Inh:HBc fusion protein is effective in eliciting an antibody response against the antigenic peptide in host animals, particularly in farm animals. Vaccination of a host animal with the Inh:HBc fusion protein results in the development of specific anti-inhibin antibodies in the animal, in the presence or absence of added adjuvant. Vaccination and induction of anti-inhibin antibodies results in enhanced fertility.

### Antigenic Inhibin Peptides

Antigenic inhibin peptides useful in the present invention are generally short amino acid sequences, e.g., less than about 100 amino acids, preferably about 8-30 amino acids, and more preferably 10-25 amino acids in length. The peptide is preferably known to represent an epitope that is able to induce an immune response against inhibin, such as the first portion of the inhibin  $\alpha_c$  chain, amino acids 1-30. For example, the antigenic peptide may be known to produce a desired antigenic response when used in another carrier protein such as HAG or when used with an adjuvant system such as co-administration with Freund's Adjuvant or other immunogen. Alternatively, the peptide antigen may be a portion of a known inhibin protein having a particularly unique amino acid sequence distinguishing it from other inhibin proteins. These and other techniques for identifying and screening potential antigenic peptides useful in vaccine development are generally known. See, for example, Scott, et al., 1990, *Science* 249:386-390.

Preferred inhibin antigenic peptides include portions of the  $\alpha_c$  chain, e.g., 10-25 amino acids selected from known antigenic portions of the molecule. Most preferred is a sequence of 10-25 amino acids of the first 30 amino acids of the  $\alpha_c$  chain.

Antigenic peptides are inserted into the HBc molecule by recombinant DNA methods. For example, a synthetic nucleic acid sequence or vector containing a nucleic acid sequence encoding a desired inhibin antigenic peptide to be inserted into HBc is specifically designed to include restriction endonuclease sites matched to a specified endonuclease-cut nucleic acid sequence encoding HBc. Where a desirable HBc insertion site contains a single, unique restriction endonuclease site, the inhibin antigen's nucleic acid sequence is preferably engineered to include matched restriction sites at both ends of the sequence. In this manner, the sequence encoding the inhibin antigen is inserted into the HBc sequence without removal of any HBc-encoding nucleotides. Care is taken to match the antigenic inhibin-encoding nucleic acid sequence to be inserted with the reading frame of the HBc sequence so that normal expression of the encoded HBc with the encoded inhibin antigen is achieved.

For HBc, specific display vectors containing cloning sites specifically engineered into the HBc nucleic acid sequence have been constructed. In these vectors, expression of the HBc gene is under the control of a tandem stretch of strong *E. coli* trp promoters. Vector pCT31, prepared as described in Borisova, et al., 1988, *Proc. USSR Acad. Sci.* 298:1474-1478 and Borisova, et al., 1989, *FEBS Lett.* 259:121-124 (containing a truncated form of HBc with amino acids 145-183 removed), is designed for insertion of antigens at amino acid position 144, and allows in-frame insertion and translation termination in all three possible frames. Vector p2-19, prepared as described in Borisova, et al., 1996, *Intervirology* 39:16-22, is designed for insertion of antigens at amino acid position 78, and allows for blunt-ended insertion of the antigenic fragment in frame.

It is contemplated that the compositions and methods of the invention may be limited by the antigenic peptide's amino acid chain length (e.g., less than 100 amino acids, and preferably no greater than about 30 amino acids), net charge of the inserted amino acid sequence (e.g., less than about 50% highly charged amino acid residues), potentially cross-linking residues, or a density of potentially self-hybridizing nucleic acid sequences. These limitations are generally known and can be recognized by review of the amino acid sequence to be inserted.

It is generally known that a nucleic acid sequence may be modified for enhanced expression in a particular host cell by modifying the codons of the nucleic acid sequence to those more preferred in the specific host cell. Thus, for example, to express the Inh:HBc fusion protein in *E. coli*, the peptide sequence is back translated into the nucleotide sequence using the codon frequency found in *E. coli* proteins, as determined, for example, by the GCG computer program (Devereaux, et al., 1984, *Nucleic Acids Res.* 12:387-3905) and modified as suggested by *E. coli* codon frequencies.

It is generally understood that protein expression in a given host cell may be enhanced by modification of one or more nucleotides in the coding sequence to reduce the number of unique or rare codons. In a preferred embodiment of the invention, the nucleic acid sequence contains one or more codons modified according to the codon frequency preferences for a particular cellular host.

### **Inhibin Vaccine**

Inhibin is a glycoprotein produced by the gonads that selectively suppresses the secretion of follicle stimulating hormone (FSH) from the anterior pituitary gland. Vaccination against inhibin decreases available inhibin, with a resulting increase in levels of follicle stimulating hormone (FSH), and enhanced fertility. Enhanced fertility may be due to enhanced production of sperm or ova, to increased rates of ovulation or spermatogenesis, or to increased lifetime proliferacy in animals, for example.

Immunization of animals with bovine inhibin -  $\alpha_c$  subunit has demonstrated the usefulness of inhibin-based antigens as fertility-enhancing vaccines. However, to date, a practical commercial vaccine has not been produced, at least in part due to the limitations of chemical synthesis, conjugation, and adjuvant toxicity discussed above.

In a preferred embodiment and exemplary of the invention, the nucleic acid sequence encoding the first 25 N-terminal residues of the antigenic inhibin  $\alpha_c$  subunit ( $\alpha_c^{1-25}$ ) is inserted into nucleic acid sequence encoding HBc such that the expressed fusion protein will include the inhibin antigenic peptide inserted at HBc amino acid position 78 (Inh:HBc-78). Multiple copies of the antigen may be



inserted, e.g., at more than one site in the HBc molecule, and preferably at two or more sites, where at least one inhibin antigen insertion site is at position 78.

The chimeric gene encoding the Inh:HBc fusion protein is subcloned into an expression vector, preferably a broad-host-range expression vector. The inserted antigen is expressed with expression of the HBc molecule, such that when the expressed fusion protein is administered to host animals, an anti-inhibin immune response is produced in the animals, reducing endogenous inhibin and thereby enhancing fertility in treated animals.

### **Hepatitis B Capsid Protein**

The hepatitis B capsid protein (HBc) is an immunogenic carrier protein having several advantages over other potential carrier molecules (Nassal, et al., *Trends in Microbiology* 1:221-228, 1993). These advantages include high level production and correct assembly into core particles in the absence of virus in a wide variety of eukaryotic and prokaryotic expression systems. Because recombinant HBc molecules expressed in *E.coli* self-assemble into particles containing 180 or 240 subunits, an inserted inhibin antigen is present in 180 or 240 copies per particle.

A hepatitis B capsid fusion protein including an antigenic inhibin peptide, capable of inducing the production of anti-inhibin antibodies in a host animal, preferably in the absence of adjuvant, would be very useful, particularly for enhancing the fertility of farm animals.

### **Cellular Hosts**

Many known cellular host systems are suitable for expression of the chimeric genes of the invention. For example, non-pathogenic strains such as *Vibrio* and including *Vibrio anguillarum* are transfected with suitable vectors containing the gene encoding Inh:HBc and express the fusion protein. Suitable vectors for use in *Vibrio* include pJF118, as described in Furst, et al, 1986, *Gene* 48:119-131.

Additional host systems useful in the invention include *E. coli*, useful for example with the HBc display vectors described more fully in the examples below, as well as other known host and vector systems.

HBc is a known immunogen. The fusion protein immunogen of the invention, formed of the intact HBc protein and an inserted antigenic inhibin peptide, is administered to farm animals such as sheep, pigs, horses, cows, and the like, according to the methods known as effective for the immunogenic administration of HBc and other protein immunogens.

Administration methods include injection, e.g., intramuscular, subcutaneous, or intraperitoneal injection and nasal administration of protein compositions to induce effective antibody titers. In a preferred embodiment, the fusion protein of the invention is expressed in edible plants or animals for oral ingestion. This oral delivery method has been described for immunogenic delivery of the immunogen LTB. See, for example, Mason, et al., 1995, *TIBTECH* 13:388-392, describing oral immunization against LTB via ingestion of transgenic potato tubers expressing LTB antigen.

### Examples

The present invention may be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention.

#### Example 1

##### Production of In:HBc Fusion Protein

##### **HBc Display Vectors**

Hepatitis B capsid antigen display vectors containing the HBc gene under the control of a tandem string of strong *E.coli* trp promoters (Borisova, et al., 1988, *Proc. USSR Acad.Sci.* 298:1474-1478; Borisova, et al., *FEBS Lett.* 259:121-124, 1989; and Borisova, et al., 1996, *Intervirology* 39:16-22) were used to insert the bovine inhibin  $\alpha_c^{1-25}$  (bINH- $\alpha_c^{1-25}$ ) antigenic epitope into HBc at amino acid positions 144 and 78. Vector pCT31 was used for insertions into position 144, and allowed in-frame insertion and translation termination in all three possible frames to produce In:HBc-144. Vector p2-19 was used for insertions into position 78, allowing for blunt-ended insertion of the antigenic fragment in frame to produce In:HBc-78.

### Inhibin Antigenic Peptide

The Inhibin antigenic peptide was prepared by synthesizing the following oligonucleotides:

5' -TCT ACC CCG CCG CTG CCG TGG CCG TGG TCC CCG  
GCT GCT CTG CTG CAG CGT CCG CCG GAA GAA CCG  
GCT GCT CCG-3' [SEQ.ID.NO:1]; and

3' -CGG AGC AGC CGG TTC TTC CGG CGG ACG CTG CAG  
CAG AGC AGC CGG GGA CCA CGG CCA CGG CAG CGG  
CGG CCT AGA-5' [SEQ.ID.NO:2].

Each oligonucleotide was phosphorylated by T4 polynucleotide kinase, and the pair of oligonucleotides was annealed to form a double-strand. The double-stranded nucleic acid sequence was then cloned as a blunt-ended fragment into the HBc display vectors to form chimeric genes encoding the Inh:HBc fusion proteins.

### Cloning

Ampicillin-resistant plasmid pCT31 carrying the C-terminally truncated (having amino acids 145-183 removed) HBc gene was used as a vector. For insertion at amino acid 144, the vector was cleaved with *Sma*I (IMB Fermentas, Vilnius, Lithuania) at position 1741, purified from agarose gel by the DEAE paper method, and used for ligation with the inhibin antigenic double-stranded nucleic acid sequence described above as phosphorylated or dephosphorylated by bacterial alkaline phosphatase (IMB Fermentas). Ligation was performed in 20 mM TRIS pH 7.6, 0.5 mM MgCl<sub>2</sub>, 5mM dithiothreitol (in 10 µl) with 100 ng vector and fragment, 1 Weiss unit of T4 DNA ligase, at 4°C for 12 hours. The molar ratio of oligonucleotide:vector was either 5:1 or 100:1.

For insertion at amino acid 78, ampicillin-resistant plasmid p2-19 carrying the HBc gene with a polylinker inserted at position 78 was also used as a vector. Polylinker encodes an immunomarker sequence "DPAFR" recognized by monoclonal anti-preS1 antibody MA18/7 (W.H.Gerlich, Giessen). The p2-19 vector was cleaved simultaneously by *Eco* 721 (position 1531) and *Eco* 1051 (position

1552) (IBM Fermentas), purified from agarose gel by DEAE paper method, dephosphorylated by bacterial alkaline phosphatase, and used for ligation with the double-stranded antigenic inhibin peptide. The oligonucleotide:vector molar ratio was 100:1.

First selection of plasmids containing the antigenic inhibin insert was by *Pst*I cleavage. The vector contains a unique *Pst*I cleavage site at position 4742. Clones containing the *Pst*I site in the insert (presenting two fragments) were subjected to further screening by immunoblotting and sequencing.

### **Purified fusion protein**

*E. coli* strain RR1 (F<sup>-</sup>, hsd S20 (r<sub>b</sub><sup>-</sup>, m<sub>b</sub><sup>-</sup>), recA<sup>+</sup>, ara-14, proA2, lacY1, galK2, rpsL20 (Sm<sup>r</sup>), xyl-5, mlt-1, supE44, λ<sup>-</sup>) was used for transformation with the chimeric Inh:HBc vectors, resulting in a transformation efficiency of 10<sup>9</sup> clones/μg of supercoiled DNA. Recombinant fusion protein was purified from cells by cell lysis followed by Sepharose CL4B column chromatography. Production yield for the fusion protein Inh:HBc-144 was higher than for Inh:HBc-78, generating 5 mg of purified intact product per liter of *E. coli* cells.

### **Immunoblot Screening**

Transformed *E. coli* cells expressing the fusion protein were selected by immunoblotting and sequencing. For selection by immunoblotting, *E. coli* strain K802 cells harboring the appropriate plasmids were grown to saturation overnight in M9 synthetic medium supplemented with 2%g/l Casamino acids (Difco). Bacteria were pelleted, suspended in SDS-gel electrophoresis sample buffer containing 2% SDS and 2% 2-mercaptoethanol, and lysed by heating at 100°C for five minutes. Proteins were separated by PAGE in a slab gel (150X150X0.75 mm) apparatus.

Western blotting was conducted as described by Towbin et al., *PNAS* USA, 76:4350-4354, 1979. Aliquots (4μg) of the fusion proteins In3-69 and In4-56, as well as control vector HBc were subjected to 15% SDS-PAGE under non-reducing conditions. Each gel was stained for protein by the silver stain method described, for example, in Ohsawa, et al., *Anal. Biochem.* 135:409-415, 1983.

Parallel gels containing 100ng aliquots of the fusion protein and control HBc were run under both non-reducing and reducing conditions. Separated protein was electrophoretically transferred to Immobilon P membrane (Millipore), and processed for immunoblot assay with mink anti-bovine  $\alpha_c^{1-26}$  gly.tyr antiserum as described in Good, et al., *Biol.Reprod.* 53:1478-1488, 1995. The protein-transferred membranes were incubated with the anti-inhibin antibody at a dilution of 1:1000 in TTBS overnight at room temperature, as described in Ireland, et al., *Biol.Reprod.* 50:1265-1276, 1994.

After washing in TTBS (five 10-minute washes), the membranes were further incubated in 20 ml of  $^{125}\text{I}$ -bINH $\alpha_c^{1-26}$  gly.tyr ( $1 \times 10^6$  cpm/ml in TTBS with 1% gelatin) for competition. The membrane was washed and placed on X-ray film (Kodak X-OMAT AR) with a Cronex intensifying screen and exposed for ten days at  $-80^\circ\text{C}$ .

As show in Figures 1A-D, the silver-stained gels as compared with the immunoblots demonstrated the purity of the fusion protein preparations. The immunoblots further demonstrated immunoreactivity of the fusion proteins with anti-inhibin antibody.

#### DNA sequencing of positive clones

The primary structure of the DNA insert in the positive clones was determined by DNA sequencing, using standard methods for Sanger's dideoxy sequencing. Two different clones were selected for sequence analysis, the first having the inhibin epitope inserted at amino acid position 144 (Inh:HBc-144) and the second inserted at amino acid position 78 (Inh:HBc-78). The following sequences were identified, confirming the insertion of the antigenic inhibin peptide sequence shown below surrounded by HBc-polylinker sequences (in bold):

In position 144, clone In3-38, encoding Inh:HBc-144:

```
GGG CCC TCT ACC CCG CCG CTG CCG TGG CCG TGG TCC
Gly Pro Ser Thr Pro Pro Leu Pro Trp pro Trp Ser

CCG GCT GCT CTG CTG CAG CGT CCG CCG GAA GAA CCG
Pro Ala Ala Leu Leu Gln Arg Pro Pro Glu Glu Pro

GCT GCT CCG GGG TAA [SEQ.ID.NO:3]
```

Ala Ala Pro **Gly** [SEQ.ID.NO:4]

In position 78, clone In4-56, encoding Inh:HBc-78:

**GAT CAC** TCT ACC CCG CCG CTG CCG TGG CCG TGG TCC  
**Asp His** Ser Thr Pro Pro Leu Pro Trp pro Trp Ser

CCG GCT GCT CTG CTG CAG CGT CCG CCG GAA GAA CCG  
 Pro Ala Ala Leu Leu Gln Arg Pro Pro Glu Glu Pro

GCT GCT CCG **GTA GAT** [SEQ.ID.NO:5]

Ala Ala Pro **Val Asp** [SEQ.ID.NO:6]

### Self-Assembly

The Inh:HBc fusion protein self-assembled and remained intact after insertion of the antigenic inhibin peptide into HBc, as shown by double radial immunodiffusion against capsid specific antibodies, using the method of Ouchterlony, 1965, In: *Immunochemie. 15th Colloquium of the Gesellschaft fur Physiologische Chemie*, Springer, Berlin, Heidelberg, New York, 1979, pages 15-35. Gel filtration on Separose CL4B, and electron microscopy of negatively stained Inh:HBc fusion protein capsid preparations were also used to confirm correct assembly.

Natural human and hyperimmune rabbit anti-HBc antibodies were used as the particulate HBc-specific polyclonal antibodies for double radial immunidiffusion test according to Ouchterlony, *supra*. Hyperimmune anti-HBc antibodies were generated by immunization of rabbits with purified recombinant HBc (Mezule, BMC, Riga).

Ouchterlony's test for lysozyme lysates of the fusion proteins demonstrated their full capability to self-assemble. Ouchterlony's assay employs the basic principles of double radial immunodiffusion in 0.8% agarose gel of antibodies (center) and antigens at the step 1:2 dilutions (radial) after 24 hours at 4°C. Titers of antibody are recognized as the last precipitation - line-forming dilution. These studies demonstrated the two fusion protein clones, Inh:HBc-144 (In3-38) and Inh:HBc-78 (In4-56) were able to form capsids (see Figure 2).

### Purification of Fusion Protein

Inh:HBc recombinants 144 (In3-38) and 78 (In4-56) were expressed in *E. coli* strain K802 harboring the appropriate plasmid encoding a recombinant gene under the control of a tandem string of strong bacterial *trp* promoters. Bacteria were grown overnight on a rotary shaker at 37°C in 500 ml flasks containing 200 ml of M9 minimal medium supplemented with 1% Casamino acids (Difco) and 0.2% glucose. An optical density (650 nm) of 4-5 for one ml of the suspension was generally reached. Cells were pelleted and lysed with a 30 minute incubation on ice in lysis buffer containing 50 mM TRIS-HCl (ph 8.0), 5 mM EDTA, 100 µg/ml PMSF, 2 mg/ml lysozyme and then frozen and thawed three times. After freeze-thaw, 10mM MgCl<sub>2</sub> and 20 µg/ml DNase were added. After low speed centrifugation, proteins were precipitated from the supernatant with ammonium sulphate at 30% saturation for 12 hours at 4°C. Pellets were resuspended in standard PBS buffer containing 0.1% Triton X-100 (30-40 mg/ml total protein). A volume of 5 ml of protein solution was loaded on a Sepharose CL4B column (2.5 x 85 cm) and eluted with PBS buffer without Triton X-100. Fractions containing capsids (detected by double radial immunodiffusion test against human polyclonal anti-HBc antibodies) were pooled and concentrated by ammonium sulphate precipitation at 50% saturation. Pellets were resuspended in TRIS-saline buffer (10 mM TRIS-HCl (pH 7.5), 150 mM NaCl) to a final concentration of about 10-15 mg/ml total protein, dialyzed overnight against 1000 volumes of the same buffer and stored at -70°C. Quality of capsid preparations was checked by electron microscopy (V.Ose, BMC, Riga). See Figure 2.

Immunodiffusion, silver stained PAGE, and immunoblots with anti-HBc monoclonal 14E11 antibodies of SDS and lysozyme lysates of Inh:HBc-144 and Inh:HBc-78 cells were used to follow the purification process. On silver staining and immunoblot of gels run with the fusion protein, the inhibin fusion protein preparation was shown to be relatively pure. The immunoblot data demonstrated that only the fusion protein, and not the HBc vector reacted with anti- $\alpha_c^{1-25}$  antibodies. (See Figures 1A-D).

**Example 2****Immunization of Mice with Inh:HBc Fusion Protein**

A total of 45 BALB/C mice, 5 per treatment group, were immunized subcutaneously with 20  $\mu$ g of the Inh:HBc fusion proteins 144 (In3-96) and 78 (In4-56), or with the HBc control, both in the presence and absence of Freund's complete adjuvant (0.1ml). One group of mice was untreated. The primary immunization was followed by four boosters spaced two weeks apart. Two weeks after boosts 1, 2, and 3, all mice were bled. A volume of 20  $\mu$ l of blood was placed in PBS (1:10 dilution) containing heparin to prevent clotting. Each boost was given immediately following each bleed. Mice were sacrificed 2 weeks after boost 4, and trunk blood was collected.

The blood samples were analyzed for anti-inhibin antibody activity by ELISA. Microtiter plates (Xenobind, Xenopore, Inc.) were coated with 1  $\mu$ g/well of bovine inhibin  $\alpha_c^{1-26}$  peptide, and a solid phase, non-radiometric ELISA protocol was used to estimate titer. Absorbance at 490 nm ( $A_{490}$ ) was measured using a microplate reader (BioRad Model 35500). Titer was defined as the serum/plasma dilution giving an  $A_{490}$  four times the average value for untreated controls.

The  $A_{490}$  for blood samples of HBc-treated mice were not different than the untreated control samples (data not shown). As shown in Figure 3, significant antibody titers against the  $\alpha_c^{1-26}$  inhibin fragment were elicited in all mice immunized with either Inh:HBc-144, Inh:HBc-78, with Freund's adjuvant (+FR), and importantly, in the absence of the adjuvant. Mice immunized with Inh:HBc-78 plus Freund's adjuvant demonstrated the highest titer. The values shown in the figure represent the mean  $\pm$  SEM of pooled mouse titers for Boost 1, but individual mouse titers for Boosts 2-4 are shown.

The immunogenic blood samples were further tested for their ability to recognize native inhibin. Microtiter test plates were coated with 1  $\mu$ g of a partially purified preparation of bovine inhibin, prepared as described in Good, et al., *Biology Reprod.* 53:1478-1488, 1995. The native inhibin preparation contains nine different molecular variants of bovine inhibin dimers and  $\alpha$  subunits. Titer was determined for mouse serum collected after Boost 4. The  $A_{490}$  values for HBc-treated mice did not differ from the untreated control (data not shown). Figure 4 shows  $A_{490}$  values as



mean  $\pm$  SEM of individual mouse titers for each treatment group after Boost 4. The results demonstrate that mice immunized with any of the HBc- Inhibin fusion proteins, with or without adjuvant, produced antibodies capable of reacting with native inhibin. The Inh:HBc-78 (In4-56) fusion protein produced the highest antibody titers, with or without added adjuvant.

### Example 3

#### Intraperitoneal immunization of mice with Inh:HBc

Mice (5 per treatment group) were immunized intraperitoneally with the Inh:HBc fusion proteins Inh:HBc-144 and Inh:HBc-78 or with HBc mixed in Freund's adjuvant. A boost was given 24 days after primary injection, and titer was determined 7 days after the boost, using the methods described above for Example 2.

In the analysis of antibody titer, serum was pooled for all mice in a treatment group, and 2 $\mu$ g of the inhibin antigen  $\alpha_c^{1-26}$  was added to each well of Maxisorp, NUNC plates. Both controls and treated animals exhibited high titers against HBc (data not shown). Importantly, antibodies against the inhibin antigen were detected for all mice immunized with Inh:HBc-144 or Inh:HBc-78, but not the HBc control (see Table 1). The titers of anti-inhibin antibodies elicited by Inh:HBc-78 were 5 times the level elicited by Inh:HBc-144, and with greater specificity for the inhibin antigen versus the carrier HBc molecule.

Table 1

Immunogen	Anti-HBc Titer	Anit-Inhibin Titer
Inh:HBc-144	1:10,000	1:3,000
Inh:HBc-78	1:500	1:15,000
HBc	1:100,000	-

### Example 4

#### Immunization of Gilts with HBcAg: $\alpha_c^{1-25}$ Fusion Protein

Latvian White gilts, 2 gilts per treatment group, were administered a single dose of 1 mg (0.8 ml) of Inh:HBc fusion protein, Inh:HBc-144 or Inh:HBc-78,

or with HBc control, mixed in 0.8 ml Freund's Complete Adjuvant. Injections were made into multiple sites across each animal's back. Blood samples were collected and titers against the antigenic inhibin 1-26 peptide were determined, as described above for Example 2, assaying individual animal titers.

Within ten days after the single injection, the two gilts immunized with Inh:HBc-78 had developed anti-inhibin titers of 1:600 and 1:125, which increased to 1:3000 and 1:600, respectively, by 19 days after the injection, as shown in Figure 5. The two gilts immunized with Inh:HBc-144 had titers of 1:125 or less, and the two gilts immunized with HBcAg had non-detectable titers. Thirty days after the primary immunization, the titre determined for each gilt was determined. The 30 day data are shown below in Table 2.

**Table 2**

Immunogen	anti-HBc		anti-inhibin	
Inh:HBc-78	1:10,000	1:10,000	1:15,000	1: 3,000
Inh:HBc-144	1:100,000	1:1,000,000	1:100	1:125
HBc	1:100,000	1:100,000		-

These results demonstrate that an HBcAg: $\alpha_c$ <sup>1-25</sup> fusion protein, Inh:HBc-78, is highly immunogenic in gilts, as well as in mice, and the immunogenicity is demonstrated in the absence of adjuvant. The data further demonstrate that an inhibin antigenic peptide, when inserted at position 78 of HBc, induces a useful antibody titre with preferred anti-inhibin specificity.

## WE CLAIM:

1. A nucleic acid construct comprising:  
a first nucleic acid sequence encoding an inhibin antigenic peptide;  
and  
a second nucleic acid sequence encoding a hepatitis B capsid protein,  
wherein the first sequence is inserted into the second sequence to  
encode a fusion protein having the inhibin antigenic peptide inserted at position 78  
of the hepatitis B capsid protein.
2. The nucleic acid construct of claim 1, wherein said second nucleic  
acid sequence encoding hepatitis B capsid protein is truncated to remove nucleic  
acid residues 145-183.
3. The nucleic acid construct of claim 1, wherein the inhibin antigenic  
peptide comprises an antigenic portion of the  $\alpha_c$  chain.
4. The nucleic acid construct of claim 1, wherein the inhibin antigenic  
peptide comprises a sequence of 10 or more of amino acids 1-30 of inhibin  $\alpha_c$ .
5. The nucleic acid construct of claim 1, wherein the inhibin antigenic  
peptide comprises inhibin- $\alpha_c^{1-25}$ .
6. A fusion protein comprising:  
hepatitis B capsid protein; and  
an inhibin antigenic peptide,  
wherein the inhibin antigenic peptide is inserted at amino acid 78 of  
the hepatitis B capsid protein.
7. The fusion protein of claim 6, wherein the inhibin antigenic peptide  
comprises an antigenic portion of the  $\alpha_c$  chain.

8. The fusion protein of claim 6, wherein the inhibin antigenic peptide comprises a sequence of 10 or more of amino acids 1-30 of inhibin  $\alpha_c$ .
9. The fusion protein of claim 6, wherein the inhibin antigenic peptide comprises inhibin- $\alpha_c^{1-25}$ .
10. A method for producing an anti-inhibin immunogen, the method comprising the steps of:  
inserting a first nucleic acid sequence encoding an inhibin antigenic peptide into a second nucleic acid sequence encoding hepatitis B capsid protein to form a fusion construct expressing a fusion protein having the inhibin antigenic peptide inserted at position 78 of the hepatitis B capsid protein;  
expressing the fusion protein in a host cell.
11. The method of claim 10, wherein the inhibin antigenic peptide comprises an antigenic portion of the inhibin  $\alpha_c$  chain.
12. The method of claim 10, wherein the inhibin antigenic peptide comprises a sequence of 10 or more of amino acids 1-30 of inhibin  $\alpha_c$ .
13. The method of claim 10, wherein the inhibin antigenic peptide comprises inhibin- $\alpha_c^{1-25}$ .
14. A method of inducing an anti-inhibin immune response in a host animal comprising the steps of:  
administering to a host animal a fusion protein comprising a hepatitis B capsid protein having an inhibin antigenic peptide inserted at position 78.
15. The method of claim 14, wherein the inhibin antigenic peptide comprises an antigenic portion of the  $\alpha_c$  chain.

16. The method of claim 14, wherein the inhibin antigenic peptide comprises a sequence of 10 or more of amino acids 1-30 of inhibin  $\alpha_c$ .
17. The method of claim 14, wherein the inhibin antigenic peptide comprises bovine inhibin- $\alpha_c^{1-25}$ .
18. The method of claim 14, wherein said host animal is swine.
19. The method of claim 14, wherein said administering is in the absence of adjuvant.

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D







FIG. 2






**FIG. 3**      Inh:HBc-78+Fr    Inh:HBc-78    Inh:HBc-144+Fr    Inh:HBc-144







## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: MICHIGAN STATE UNIVERSITY
- (ii) TITLE OF THE INVENTION: INHIBIN-HBc FUSION PROTEIN
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Merchant, Gould, Smith, Edell, Welter & Schmidt
  - (B) STREET: 3100 Norwest Center, 90 South 7th Street
  - (C) CITY: Minneapolis
  - (D) STATE: MN
  - (E) COUNTRY: USA
  - (F) ZIP: 55402
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: NEW FILING
  - (B) FILING DATE: 04-APRIL-1999
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 09/072,323
  - (B) FILING DATE: 04-MAY-1998
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Kettelberger, Denise M
  - (B) REGISTRATION NUMBER: 33,924
  - (C) REFERENCE/DOCKET NUMBER: 11526.2WO01
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 612-332-5300
  - (B) TELEFAX: 612-332-9081
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 75 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCTACCCCGC CGCTGCCGTG GCCGTGGTCC CCGGCTGCTC TGCTGCAGCG TCCGCCGGAA  
GAACCGGCTG CTCCG

60  
75

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
AGATCCGGCG GCGACGGCAC CGGCACCAGG GGCCGACGAG ACGACGTCGC AGGCGGCCTT 60
CTTGCCCGAC GAGGC 75
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 89 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
GGGCCCTCTA CCCC GCCGCT GCCGTGGCCG TGGTCCGYCC GGCTGCTCTG CTGCAGCGTC 60
CGCCGGAAGA ACCGGCTGCT CCGGGGTAA 89
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Gly Pro Ser Thr Pro Pro Leu Pro Trp Trp Ser Pro Ala Ala Leu Leu
 1           5           10           15
Gln Arg Pro Pro Glu Glu Pro Ala Ala Pro Gly
 20           25
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GATCACTCTA CCCC GCCGCT GCCGTGGCCG TGGTCCCCGG CTGCTCTGCT GCAGCGTCCG 60
CCGGAAGAAC CGGCTGCTCC GGTAGAT 87
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Asp	His	Ser	Thr	Pro	Pro	Leu	Pro	Trp	Trp	Ser	Pro	Ala	Ala	Leu	Leu
1				5				10						15	
Gln	Arg	Pro	Pro	Glu	Glu	Pro	Ala	Ala	Pro	Val	Asp				
			20					25							

18



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/62, 15/16, 15/36, C07K 14/575, 14/02</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/57289</b> <b>(43) International Publication Date:</b> 11 November 1999 (11.11.99)
<b>(21) International Application Number:</b> PCT/US99/08238 <b>(22) International Filing Date:</b> 14 April 1999 (14.04.99)  <b>(30) Priority Data:</b> 09/072,323      4 May 1998 (04.05.98)      US  <b>(71) Applicant:</b> MICHIGAN STATE UNIVERSITY [US/US]; 238 Administration Building, East Lansing, MI 48824-1046 (US).  <b>(71)(72) Applicants and Inventors:</b> PUMPENS, Paul [LV/LV]; Baznicas 27/29-21, LV-1010 Riga (LV). BORISOVA, Galina [LV/LV]; Merkela 2-6, LV-1050 Riga (LV). SKRASTINA, Dace [LV/LV]; Dammes 34-10, LV-1069 Riga (LV). MEZULE, Guna [LV/LV]; Skujenes 10-1, LV-1055 Riga (LV).  <b>(72) Inventor:</b> IRELAND, James, J.; 2805 Brentwood Avenue, East Lansing, MI 48823 (US).  <b>(74) Agent:</b> DAIGNAULT, Ronald, A.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-4131 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 17 February 2000 (17.02.00)
<b>(54) Title:</b> INHIBIN-HBc FUSION PROTEIN  <b>(57) Abstract</b>  A fusion protein formed of an antigenic inhibin peptide inserted into hepatitis B capsid protein is expressed from a chimeric gene forming an effective immunogen which induces anti-inhibin antibodies when administered to a host animal.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/08238

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C12N15/16 C12N15/36 C07K14/575 C07K14/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GEARY T W ET AL: "Production of a genetically engineered inhibin vaccine" VACCINE, vol. 14, no. 13, 1996, page 1273-1279 XP004069598 ISSN: 0264-410X the whole document	1-19
Y	BORISOVA G ET AL: "Spatial structure and insertion capacity of immunodominant region of Hepatitis B core antigen" INTERVIROLOGY, vol. 39, no. 1-2, November 1996 (1996-11), pages 16-22, XP002125539 cited in the application the whole document	1-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 December 1999

Date of mailing of the international search report

29/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/US 99/08238

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 40219 A (AGRITECH TECHNOLOGIES LTD ;UNIV LOUISIANA STATE (US)) 19 December 1996 (1996-12-19) the whole document ---	1-19
A	ULRICH R ET AL: "CORE PARTICLES OF HEPATITIS B VIRUS AS CARRIER FOR FOREIGN EPITOPES" ADVANCES IN VIRUS RESEARCH,US,SAN DIEGO, CA, vol. 50, page 141-182 XP000856161 page 151 -page 155; table II -----	1-19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/08238

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 14-19  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08238

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640219 A	19-12-1996	US 5725858 A	10-03-1998
		AU 6094196 A	30-12-1996
		CA 2222947 A	19-12-1996
		CN 1192692 A	09-09-1998
		EP 0833658 A	08-04-1998
		JP 11511964 T	19-10-1999
		PL 323865 A	27-04-1998
		US 5747659 A	05-05-1998

Form PCT/ISA/210 (patent family annex) (July 1992)